Hence, in this paper we performed a retrospective multicenter study and analyzed the details of R/R B‐cell lymphoma patients who received CD19 targeted CAR‐T heretofore in five cellular immunotherapy centers in China during the omicron wave, trying to provide suggestions on CAR‐T whole‐course management for COVID‐19. The gene discussed is CD19; the disease is B-cell non-Hodgkin lymphoma.